Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
9x6WWJCkqNApUrCE
